Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression

Acta Pharmacologica Sinica

Volumn 31, Issue 10, 2010, Pages 1367-1375

  Wu, Jing ^b   Zhao, Miao Yun ^a   Zheng, Hao ^b   Zhang, Hua ^a   Jiang, Ying ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

advanced glycation end products; advanced glycation end products receptors; atherosclerosis; nonalcoholic steatohepatitis; pentoxifylline

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ASPARTATE AMINOTRANSFERASE; GLUCOSE; MESSENGER RNA; PENTOXIFYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CONTROLLED STUDY; FEEDING; GLUCOSE BLOOD LEVEL; LIPID DIET; LIVER FUNCTION; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ANIMALS; ATHEROSCLEROSIS; DIETARY FATS; FATTY LIVER; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC;

EID: 77957728142     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.110     Document Type: Article

References (44)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
3. Matteoni CA, Younossi ZM, Gramlich T, Bopari N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
5. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxeamia, and tumor necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001;48:206-11.
6. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
7. Szczepanik AM, Wordliczek J, Serednicki W, Siedlar M, Czupryna A. Pentoxifylline does not affect nociception if administered postoperatively. Pol J Pharmacol 2004;56:611-6
8. Abdel-Salam O M E, Baiuomy AR, El-Shenawy SM, Arbid MS. The antiinflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 2003;47:331-40.
9. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
10. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8.
11. Zhang L, Jia JD, Zhang H, Wang D, An W. Therapeutic effects of pentoxifylline on rat nonalcoholic steatohepatitis is mediated by lowering tumor necrosis factor alpha. Liver 2007;12:261-4.
12. Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci 2001;6:1151-60.
13. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated athero sclerosis in diabetes. Cardiovasc Res 2004;63:582-92. (Pubitemid 39078671)
14. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
15. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
16. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004;53:166-72.
17. Gao X, Zhang H, Marie A, Zhang SC. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008;295: H491-H498.
18. Takeda R, Suzuki, E, Satonaka H, Oba S, Nishimatsu H, Omata M, et al. Blockade of endogenous cytokines mitigates neointimal formation in Obese Zucker rats. Circulation 2005;111:1398-406.
19. Falcone C, Emanuele E, D'Angelo AP, Buzzi M, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-7. (Pubitemid 40627851)
20. Horiuchi S. The liver is the main site for metabolism of circulating sdvanced glycstion end products. J Hepatology 2002;36:123-5.
21. Sebekova K, Kupcova V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatology 2002;36:66-71.
22. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibro blasts. Hepatology 2001;34:943-52.
23. Jiang Y, Zhang H, Dong LY, Wang D, An W. Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. J Cell Biochem 2008;105:277-89.
24. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002;50:241-7.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
26. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250-6.
27. Promrat K, Lutchman G, Uwaifo GI. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
28. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
29. Koppe S W P, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatology 2004;41:592-8.
30. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec 2008;291:684-92.
31. Suren A, Bauer FE, Rosenkranz B. Effect of pentoxifylline on liver plasma flow in normal man. Eur J Clin Pharmacol 1991;41:233-7.
32. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:634-8.
33. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
34. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-30. (Pubitemid 44125930)
35. O'Leary DH, Polak JF. Intima-media thickness: a tool for athero sclerosis imaging and event prediction. Am J Cardiol 2002;90:18-21.
36. Aygun C, Kocaman O, Sahin T, Uraz S, Eminler AT, Celebi A, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008;53:1352-7.
37. Glagov S, Weisenberg E, Zarins CK. Compensatory enlargement of human atherosclerotic coronary arteries. N Eng J Med 1987;316:371-5.
38. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and s100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275:40096-100.
39. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002;4:228-37.
40. Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE. Divergent pathways o gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 2004;53:743-51
41. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function Arterioscler Thromb Vasc Biol 2000;20: E83-E88
42. Rahbar S, Natarajan R, Yerneni KK, Scott S, Gonzales N, Nadler LJ. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000;301:65-77
43. Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997;273 G1094-100
44. Hernández E, Bucio L, Souza V, Escobar MC, Gómez-Quiroz LE, Farfán B, et al. Pentoxifylline downregulates α (I) collagen expression by the nhibition of IκBα degradation in liver stellate cell. Cell Biol Toxico 2008;24:303-14